SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
SEC Accession No. 0001479290-22-000065
Filing Date
2022-05-13
Accepted
2022-05-13 18:08:58
Documents
1
Period of Report
2022-05-04

Document Format Files

Seq Description Document Type Size
1 FORM 4/A wf-form4a_165247967703233.html 4/A  
1 FORM 4/A wf-form4a_165247967703233.xml 4/A 4462
  Complete submission text file 0001479290-22-000065.txt   5874
Mailing Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203
Business Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203 6157247755
Revance Therapeutics, Inc. (Issuer) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O LEVI STRAUSS & CO. 1155 BATTERY STREET SAN FRANCISCO CA 94111
Business Address
Beraud Jill (Reporting) CIK: 0001520061 (see all company filings)

Type: 4/A | Act: 34 | File No.: 001-36297 | Film No.: 22924402